Other

Chiesi Farmaceutici S.p.a.

Apotex Inc.

Apotex USA Inc.

Bernard Charles Sherman

Michael Spino

Navin Vaya

Arunprasath Kaliaperumal

Krishna Hari Bhandari

Sandeep Patel

The present invention relates to extended release pharmaceutical dosage forms of oxcarbazepine.

Oxcarbazepine extended release dosage form

The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Delayed release deferiprone tablets and methods of using the same

Provided is a pharmaceutical formulation comprising lubiprostone and at least one propylene glycol ester. The propylene glycol ester is typically selected from the group consisting of: propylene glycol mono-ester of lauric acid, propylene glycol mono-ester of caprylic acid, propylene glycol mono-ester of capric acid, propylene glycol di-ester of lauric acid, propylene glycol di-ester of caprylic acid and propylene glycol di-ester of capric acid.

Stable pharmaceutical formulations comprising lubiprostone

Stable tablets comprising fosinopril sodium are prepared by employing either stearic acid or zinc stearate as the lubricant.

Fosinopril sodium tablet formulation

Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.

Clopidogrel bisulfate tablet formulation

A process of producing the magnesium salt of an enantiomer of omeprazole, said process comprising the steps of:

Magnesium salt of S-omeprazole

Stable solid compositions comprising moxeipril magnesium can be made using moexipril or an acid addition salt thereof, by reacting the moxeipril or acid addition salt with an alkaline magnesium compound in the presence of a solvent, so as to convert most or all of the moexipril or acid addition salt to moexipril magnesium.

Pharmaceutical compositions comprising moexipril magnesium

A pharmaceutical tablet which incorporates two smaller tablets, one of which comprises an NSAID and the other of which comprises misoprostol.

Pharmaceutical tablets comprising an NSAID and a prostaglandin

Stable tablets comprising benazepril hydrochloride are prepared by employing zinc stearate as the lubricant.

Growing community of inventors

Willowdale, Canada

Bernard Charles Sherman